Tumor necrosis factor antagonist-associated neutropenia: comment on the article by Hastings et al

Arthritis Care Res (Hoboken). 2010 Dec;62(12):1813-5; author reply 1815. doi: 10.1002/acr.20317.
No abstract available

Publication types

  • Comment
  • Letter

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Antibodies, Monoclonal / adverse effects*
  • Antibodies, Monoclonal / therapeutic use
  • Antirheumatic Agents / adverse effects*
  • Antirheumatic Agents / therapeutic use
  • Female
  • Humans
  • Infliximab
  • Leukocyte Count
  • Male
  • Middle Aged
  • Neutropenia / blood
  • Neutropenia / chemically induced*
  • Prognosis
  • Rheumatic Fever / drug therapy
  • Risk Factors
  • Tumor Necrosis Factor-alpha / antagonists & inhibitors*
  • Tumor Necrosis Factor-alpha / blood
  • Young Adult

Substances

  • Antibodies, Monoclonal
  • Antirheumatic Agents
  • Tumor Necrosis Factor-alpha
  • Infliximab